Skip to main content
Top
Published in: Supportive Care in Cancer 11/2012

01-11-2012 | Short Communication

High incidence of bloodstream infection detected by surveillance blood cultures in hematology patients on corticosteroid therapy

Authors: A. Joosten, J. Maertens, J. Verhaegen, T. Lodewyck, E. Vermeulen, K. Lagrou

Published in: Supportive Care in Cancer | Issue 11/2012

Login to get access

Abstract

Purpose

The aim of our study was to evaluate the frequency of “occult” bacteremia/fungemia as well as the diversity of pathogens involved in hematology patients treated with corticosteroids.

Methods

Daily surveillance blood cultures were taken from patients treated with corticosteroids as part of their intensive chemotherapy or during graft-versus-host disease following hematopoietic stem cell transplantation during a 3-year period (2006–2009). We reviewed the frequency of occult bacteremia/fungemia as well as the pathogens involved.

Results

During the 3-year period, 3,821 bottles were cultured from 215 patients and 4.9 % of the bottles tested were positive. Surveillance blood cultures revealed bloodstream infection in 24 % of the patients (definite bloodstream infection in 16 %). Seventy-five percent of patients were still afebrile when microorganisms were detected. The main risk group was acute lymphocytic leukemia patients undergoing remission induction chemotherapy. The pathogens cultured most frequently were coagulase-negative staphylococci, enterococci, Escherichia coli, and Pseudomonas aeruginosa.

Conclusions

A high incidence of occult bacteremia was detected by surveillance blood cultures. Further studies are needed to evaluate if a strategy based on surveillance blood cultures can reduce mortality related to bloodstream infections.
Literature
1.
go back to reference Lin MY, Weinstein RA, Hota B (2008) Delay of active antimicrobial therapy and mortality among patients with bacteremia: impact of severe neutropenia. Antimicrob Agents Chemother 52:3188–3194PubMedCrossRef Lin MY, Weinstein RA, Hota B (2008) Delay of active antimicrobial therapy and mortality among patients with bacteremia: impact of severe neutropenia. Antimicrob Agents Chemother 52:3188–3194PubMedCrossRef
2.
go back to reference Weinstein MP, Towns ML, Quartey SM, Mirrett S, Reimer LG, Parmigiani G, Reller LB (1997) The clinical significance of positive blood cultures in the 1990s: a prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults. Clin Infect Dis 24:584–602PubMed Weinstein MP, Towns ML, Quartey SM, Mirrett S, Reimer LG, Parmigiani G, Reller LB (1997) The clinical significance of positive blood cultures in the 1990s: a prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults. Clin Infect Dis 24:584–602PubMed
3.
go back to reference Freifeld AG, Bow EJ, Sepkowitz KA Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR, Infectious Diseases Society of America (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52:e56–e93PubMedCrossRef Freifeld AG, Bow EJ, Sepkowitz KA Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR, Infectious Diseases Society of America (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52:e56–e93PubMedCrossRef
4.
go back to reference O’Grady NP, Barie PS, Bartlett JG, Bleck T, Carroll K, Kalil AC, Linden P, Maki DG, Nierman D, Pasculle W, Masur H, American College of Critical Care Medicine, Infectious Diseases Society of America (2008) Guidelines for evaluation of new fever in critically ill adult patients: 2008 update from the American College of Critical Care Medicine and the Infectious Diseases Society of America. Crit Care Med 36:1330–1349PubMedCrossRef O’Grady NP, Barie PS, Bartlett JG, Bleck T, Carroll K, Kalil AC, Linden P, Maki DG, Nierman D, Pasculle W, Masur H, American College of Critical Care Medicine, Infectious Diseases Society of America (2008) Guidelines for evaluation of new fever in critically ill adult patients: 2008 update from the American College of Critical Care Medicine and the Infectious Diseases Society of America. Crit Care Med 36:1330–1349PubMedCrossRef
5.
go back to reference Clinical and Laboratory Standards Institute (2007) Principles and procedures for blood cultures; approved guideline. CLSI document M47-A. Wayne, PA Clinical and Laboratory Standards Institute (2007) Principles and procedures for blood cultures; approved guideline. CLSI document M47-A. Wayne, PA
6.
go back to reference Bailey JM (1991) New mechanisms for effects of anti-inflammatory glucocorticoids. Biofactors 3:97–102PubMed Bailey JM (1991) New mechanisms for effects of anti-inflammatory glucocorticoids. Biofactors 3:97–102PubMed
7.
go back to reference Knudsen PJ, Dinarello CA, Strom TB (1987) Glucocorticoids inhibit transcriptional and post-transcriptional expression of interleukin 1 in U937 cells. J Immunol 139:4129–4134PubMed Knudsen PJ, Dinarello CA, Strom TB (1987) Glucocorticoids inhibit transcriptional and post-transcriptional expression of interleukin 1 in U937 cells. J Immunol 139:4129–4134PubMed
8.
go back to reference Chizuka A, Kami M, Kanda Y, Murashige N, Kishi Y, Hamaki T, Kim SW, Hori A, Kojima R, Mori SI, Tanosaki R, Gomi H, Takaue Y (2005) Value of surveillance blood culture for early diagnosis of occult bacteremia in patients on corticosteroid therapy following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 35:577–582PubMedCrossRef Chizuka A, Kami M, Kanda Y, Murashige N, Kishi Y, Hamaki T, Kim SW, Hori A, Kojima R, Mori SI, Tanosaki R, Gomi H, Takaue Y (2005) Value of surveillance blood culture for early diagnosis of occult bacteremia in patients on corticosteroid therapy following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 35:577–582PubMedCrossRef
9.
go back to reference Penack O, Keilholz U, Thiel E, Blau IW (2005) Value of surveillance blood cultures in neutropenic patients—a pilot study. Jpn J Infect Dis 58:171–173PubMed Penack O, Keilholz U, Thiel E, Blau IW (2005) Value of surveillance blood cultures in neutropenic patients—a pilot study. Jpn J Infect Dis 58:171–173PubMed
10.
go back to reference Penack O, Rempf P, Eisenblatter M, Stroux A, Wagner J, Thiel E, Blau IW (2007) Bloodstream infections in neutropenic patients: early detection of pathogens and directed antimicrobial therapy due to surveillance blood cultures. Ann Oncol 18:1870–1874PubMedCrossRef Penack O, Rempf P, Eisenblatter M, Stroux A, Wagner J, Thiel E, Blau IW (2007) Bloodstream infections in neutropenic patients: early detection of pathogens and directed antimicrobial therapy due to surveillance blood cultures. Ann Oncol 18:1870–1874PubMedCrossRef
11.
go back to reference Isenbergh HD (2007) Clinical microbiology procedures handbook. American Society of Microbiology Press (ASM), Washington Isenbergh HD (2007) Clinical microbiology procedures handbook. American Society of Microbiology Press (ASM), Washington
Metadata
Title
High incidence of bloodstream infection detected by surveillance blood cultures in hematology patients on corticosteroid therapy
Authors
A. Joosten
J. Maertens
J. Verhaegen
T. Lodewyck
E. Vermeulen
K. Lagrou
Publication date
01-11-2012
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 11/2012
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-012-1557-x

Other articles of this Issue 11/2012

Supportive Care in Cancer 11/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine